STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Evogene Schedules Third Quarter 2025 Financial Results Release

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Evogene (NASDAQ: EVGN) will release its third quarter 2025 financial results on Thursday, November 20, 2025. Company management will host a Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel time) to discuss the results. Investors must register in advance to attend: https://www.veidan-conferencing.com/evogene. The full conference will be available on the company website a few days after the call.

Evogene (NASDAQ: EVGN) pubblicherà i risultati finanziari del terzo trimestre 2025 il giovedì 20 novembre 2025. La direzione aziendale ospiterà una conference call Zoom nello stesso giorno alle 9:00 AM ET (4:00 PM ora di Israele) per discutere i risultati. Gli investitori devono registrarsi in anticipo per partecipare: https://www.veidan-conferencing.com/evogene. L’intera conferenza sarà disponibile sul sito web dell’azienda pochi giorni dopo la chiamata.

Evogene (NASDAQ: EVGN) divulgará sus resultados financieros del tercer trimestre de 2025 el jueves 20 de noviembre de 2025. La dirección de la empresa realizará una conferencia por Zoom el mismo día a las 9:00 AM ET (4:00 PM hora de Israel) para discutir los resultados. Los inversores deben registrarse con anticipación para asistir: https://www.veidan-conferencing.com/evogene. La conferencia completa estará disponible en el sitio web de la empresa unos días después de la llamada.

에보진(나스닥: EVGN)2025년 3분기 재무 실적2025년 11월 20일 목요일에 발표합니다. 회사 경영진은 같은 날 줌 컨퍼런스 콜동부 표준시 9:00 AM(이스라엘 시간 4:00 PM)에 개최하여 결과를 논의합니다. 투자자는 참석을 위해 미리 등록해야 합니다: https://www.veidan-conferencing.com/evogene. 전체 컨퍼런스는 발표 후 며칠 내에 회사 웹사이트에서 이용 가능하게 됩니다.

Evogene (NASDAQ: EVGN) publikera sina résultats financiers du troisième trimestre 2025 le jeudi 20 novembre 2025. La direction de l'entreprise animera une conférence téléphonique Zoom le même jour à 9h00 ET (16h00 heure d’Israël) pour discuter des résultats. Les investisseurs doivent s’inscrire à l’avance pour y assister : https://www.veidan-conferencing.com/evogene. La conférence complète sera disponible sur le site web de l’entreprise quelques jours après l’appel.

Evogene (NASDAQ: EVGN) wird seine Finanzergebnisse des dritten Quartals 2025 am Donnerstag, dem 20. November 2025 bekannt geben. Die Geschäftsführung wird am selben Tag eine Zoom-Konferenzschaltung um 9:00 Uhr ET (16:00 Uhr israelische Zeit) abhalten, um die Ergebnisse zu besprechen. Investoren müssen sich im Voraus registrieren, um teilzunehmen: https://www.veidan-conferencing.com/evogene. Die vollständige Konferenz wird wenige Tage nach dem Call auf der Unternehmenswebsite verfügbar sein.

Evogene (NASDAQ: EVGN) ستصدر النتائج المالية للربع الثالث من 2025 يوم الخميس 20 نوفمبر 2025. ستستضيف إدارة الشركة مكالمة مؤتمرات Zoom في اليوم نفسه في الساعة 9:00 صباحًا بتوقيت شرق الولايات المتحدة (4:00 مساءً بتوقيت إسرائيل) لمناقشة النتائج. يجب على المستثمرين التسجيل مسبقًا للحضور: https://www.veidan-conferencing.com/evogene. ستتوفر المؤتمر الكامل على موقع الشركة الإلكتروني بعد المكالمة ببضعة أيام.

Positive
  • None.
Negative
  • None.

Zoom conference call scheduled for November 20, 2025, 9:00 AM ET

REHOVOT, Israel, Nov. 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter of 2025, on Thursday, November 20, 2025.

Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).

To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene

The entire conference will be available online on the company's website a few days after.

About Evogene:

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.

At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.

Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation".

Learn more at: www.evogene.com.

Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg

Contact:
ir@evogene.com
+972-8-9311901

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evogene-schedules-third-quarter-2025-financial-results-release-302607252.html

SOURCE Evogene

FAQ

When will Evogene (EVGN) release its Q3 2025 financial results?

Evogene will release Q3 2025 results on Thursday, November 20, 2025.

What time is the Evogene (EVGN) earnings conference call on November 20, 2025?

The conference call is scheduled for 9:00 AM ET (4:00 PM Israel time) on November 20, 2025.

How can investors register for Evogene's (EVGN) November 20, 2025 call?

Register in advance at https://www.veidan-conferencing.com/evogene to attend the Zoom conference.

Will the Evogene (EVGN) Q3 2025 conference call be available after the live event?

Yes, the company said the entire conference will be available online on its website a few days after the call.

Which time zone is used for Evogene's (EVGN) November 20, 2025 call time?

The company lists the call at 9:00 AM Eastern Time, which is 4:00 PM Israel time.
Evogene

NASDAQ:EVGN

EVGN Rankings

EVGN Latest News

EVGN Latest SEC Filings

EVGN Stock Data

10.63M
8.63M
0.96%
1.61%
1.23%
Biotechnology
Healthcare
Link
Israel
Rehovot